Genmab — September 2018
-
study to use daratumumab, labeled with Zirconium-89 (89Zr ) through deferoxamine (DFO), known as 89Zr-DFO-daratumumab, for PET imaging of multiple myeloma https://clinicaltrials.gov/ct2/show/NCT03665155
-
ASCLEPIOS studies set back to 'recruiting' in clinicaltrials, where Novartis previously said they were fully recruited; who can explain why they would do that? https://clinicaltrials.gov/ct2/history/NCT02792231?A=17&B=18&C=merged
-
They forgot something/someone. It happens to me all the time
-
oktober 10-12 we will see 2 presentations/abstracts on Ofa at the Multiple Sclerosis summit in Berlin http://www.professionalabstracts.com/ectrims2018/iplanner/#/search
-
-
Opfølgning på tidligere chat.
-
-
overview of BCMA-targeting approaches in clinical trials http://www.evaluate.com/vantage/articles/news/first-real-challenge-multiple-myeloma-car-t-therapy
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind